Abstract
Background
Hypertension is a major risk factor for cardiovascular disease. Adoption of the Predicting Risk of Cardiovascular Disease Events risk model in the 2025 American College of Cardiology/American Heart Association guideline may substantially alter the number and characteristics of adults with untreated stage 1 hypertension who are recommended for treatment. We aimed to quantify treatment‐recommendation reclassification among adults with untreated stage 1 hypertension under the 2025 Predicting Risk of Cardiovascular Disease Events–based guideline compared with the 2017 pooled cohort equations–based guideline.
Methods
This cross‐sectional, nationally representative study used data from NHANES (National Health and Nutrition Examination Survey) 2015 to March 2020. The study population included adults aged 30 to 79 years with stage 1 hypertension, focusing on untreated participants. The exposure was the guideline‐endorse cardiovascular risk assessment framework, pooled cohort equations, and Predicting Risk of Cardiovascular Disease Events, respectively. The primary outcome was recommendation for antihypertensive pharmacotherapy.
Results
Among 1926 adults with stage 1 hypertension (weighted 32.57 million), 59.59% (19.41 million) were untreated. Under the 2025 guideline, 13.84% (95% CI, 7.06%–20.63%) of untreated adults eligible under the Predicting Risk of Cardiovascular Disease Events threshold (0.42 million) became newly eligible for pharmacotherapy compared with the 2017 guideline. Newly eligible adults were older (mean±SE, 60.48 [0.77] years) and had higher diabetes prevalence (37.74% [95% CI, 15.45%–60.04%]) than those below the treatment threshold.
Conclusions
The 2025 American College of Cardiology/American Heart Association hypertension guideline recommendations were largely concordant with the prior guideline among adults with untreated stage 1 hypertension, while still newly identifying a subset of individuals with elevated cardiometabolic risk who may benefit from earlier intervention.
Keywords: antihypertensive pharmacotherapy, hypertension guidelines, pooled cohort equations (PCEs), Predicting Risk of Cardiovascular Disease Events (PREVENTs), stage 1 hypertension
Subject Categories: Hypertension, Cardiovascular Disease, Treatment
Nonstandard Abbreviations and Acronyms
- ACC
American College of Cardiology
- AHA
American Heart Association
- NHANES
National Health and Nutrition Examination Survey
- PCEs
pooled cohort equations
- PREVENT
Predicting Risk of Cardiovascular Events
Clinical Perspective.
What Is New?
Compared with the 2017 pooled cohort equations‐based American College of Cardiology/American Heart Association guideline, the 2025 Predicting Risk of Cardiovascular Disease Events‐based American College of Cardiology/American Heart Association guideline newly recommends pharmacologic therapy for an additional 2.4 million US adults with stage 1 hypertension overall. Among those untreated, 0.42 million US adults are newly recommended for treatment.
What Are the Clinical Implications?
At the population level, treating the newly eligible group could potentially prevent about 67 477 cardiovascular disease events among US adults over 10 years and nearly 400 000 events long term.
The 2025 Predicting Risk of Cardiovascular Disease Events‐based guideline identifies a subgroup with greater cardiometabolic burden and early renal vulnerability who were not previously recommended for treatment. Earlier pharmacologic intervention in this group may help reduce future cardiovascular events.
Hypertension remains the leading preventable risk factor for cardiovascular disease (CVD), affecting an estimated 1.4 billion adults aged 30 to 79, and contributing to ∼10.9 million deaths globally in 2021. 1 , 2 About 44% of adults with hypertension are unaware of their condition, representing roughly 600 million people worldwide. 2 Among those diagnosed, only 42% receive treatment, and 21% achieve target blood pressure (BP). 3 Given this substantial global burden and the persistently low rates of awareness, treatment, and control, clinical guidelines and treatment thresholds of hypertension have continually evolved to improve early detection and timely management of hypertension.
The 2017 American College of Cardiology (ACC)/American Heart Association (AHA) hypertension guideline 4 redefined hypertension as BP ≥130/80 mm Hg, a decrease from the prior ≥140/90 mm Hg threshold. This reclassification defined stage 1 hypertension as a systolic BP of 130 to 139 mm Hg or a diastolic BP of 80 to 89 mm Hg. Pharmacologic therapy recommendations were linked to a patient's 10‐year atherosclerotic CVD (ASCVD) risk based on the pooled cohort equations (PCEs). Adults with stage 1 hypertension and a 10‐year risk ≥10%, or with coexisting CVD, diabetes, or chronic kidney disease, were advised to begin antihypertensive therapy. In contrast, those with lower risk were counseled to adopt lifestyle modification with reassessment in 3 to 6 months.
The recently published 2025 ACC/AHA hypertension guideline 5 introduced a major implementation update by adopting the Predicting Risk of CVD Events (PREVENT) equations for risk assessment and lowering the pharmacologic‐treatment threshold from 10% to 7.5%. This update reflects multiple considerations, including improved calibration and mitigation of risk overestimation in contemporary populations, broader age applicability, estimation of 10‐year total CVD risk (including heart failure) rather than ASCVD alone, as well as incorporation of kidney function and race‐free risk estimation. 6 , 7 Under the new framework, pharmacologic therapy is recommended when the 10‐year total CVD risk is ≥7.5%, potentially expanding treatment eligibility compared with the previous 10% threshold based on 10‐year hard ASCVD risk estimated using the PCEs.
No reports to date have quantified the impact of the 2025 PREVENT CVD risk model—either as a whole or by individual risk factors—on treatment eligibility among adults with untreated stage 1 hypertension, compared with the 2017 ACC/AHA guidelines. Better understanding the population impact of this shift in this guideline is essential for estimating future treatment burden. The impact of individual risk factors on treatment eligibility could support close monitoring for subgroups that postpone initiation of antihypertensive pharmacotherapy. Therefore, we aimed to quantify the impact of the revised treatment initiation threshold introduced in 2025 ACC/AHA (PREVENT‐based) hypertension guideline, as a whole and by individual risk factors, compared with the 2017 ACC/AHA (PCEs‐based) guideline among adults with stage 1 hypertension.
METHODS
The NHANES (National Health and Nutrition Examination Survey) data files and survey documentation used in this study are publicly available and can be accessed through the NHANES website at https://wwwn.cdc.gov/nchs/nhanes/. The NHANES protocol was approved by the National Center for Health Statistics Research Ethics Review Board, and written informed consent was obtained from all participants. The present study used publicly available, deidentified data and was therefore considered exempt from University of Florida institutional review board review.
Data Source and Study Design
We performed a cross‐sectional analysis using publicly available data from NHANES 2015 to March 2020 cycles. These cycles were selected to include nationally representative prepandemic data spanning periods before and after the release of the 2017 ACC/AHA hypertension guideline, while avoiding postpandemic NHANES cycles because changes in survey design and weighting after COVID‐19 limit comparability. NHANES employs a complex, multistage probability sampling design, in which participants are selected through stratification, clustering, and unequal probabilities to obtain a nationally representative sample of the US civilian, noninstitutionalized population. Survey weights, strata, and primary sampling units are therefore incorporated to account for this design and to produce unbiased national estimates. 8
Participant‐level information was linked across demographic, questionnaire, examination, laboratory, and prescription medication files using unique participant identifiers. Demographic characteristics and survey design variables were obtained from the demographics data; BP measurements from examination data; self‐reported hypertension, diabetes, smoking status, and CVD history from questionnaire data; laboratory measures including total cholesterol, high‐density lipoprotein cholesterol, fasting glucose, glycated hemoglobin, and serum creatinine from laboratory data; and medication use from prescription data. Detailed operational definitions are provided in Table S1.
Adults aged 30 to 79 years were eligible, consistent with the validated age range of the PREVENT cardiovascular risk score. We excluded participants with a prior history of ASCVD, including myocardial infarction and stroke, as both the PCEs and the PREVENT equations were developed for primary prevention populations and are not intended for risk estimation among individuals with established ASCVD. We also excluded participants with missing variables that are necessary to compute the PREVENT or PCEs 10‐year risk estimate. Among the remaining participants, all inputs used to calculate risk scores fell within clinically plausible ranges. From these eligible participants, we identified patients with stage 1 hypertension, defined as systolic BP 130 to 139 mm Hg or diastolic BP 80 to 89 mm Hg, consistent with the 2017 and 2025 ACC/AHA guidelines. 9 The final analytic cohort included all adults with stage 1 hypertension, regardless of antihypertensive treatment status (Figure 1).
Figure 1. Flow chart.

This diagram illustrates the selection of the study cohort, including the number of patients identified, exclusions, and final analytic sample before and after weighting. ASCVD indicates atherosclerotic cardiovascular disease; DBP, diastolic blood pressure; NHANES, National Health and Nutrition Examination Survey; and SBP, systolic blood pressure.
Statistical Analysis
For each eligible participant, 10‐year CVD risk was estimated using both the PREVENT 10‐year total CVD risk equation and the PCEs for 10‐year hard ASCVD risk. We applied the base PREVENT model instead of the optional “enhanced” PREVENT model incorporating glycated hemoglobin or urine albumin‐to‐creatinine ratio, as the base model performs well in lower‐risk populations and enhances generalizability by relying on routinely available clinical measures, particularly in settings where laboratory testing may be incomplete. 10 Inputs for the PREVENT model included age, sex, systolic BP, total cholesterol, high‐density lipoprotein cholesterol, diabetes status, current smoking status, lipid‐lowering therapy use, antihypertensives use, and estimated glomerular filtration rate (eGFR), with eGFR calculated from serum creatinine using the 2021 Chronic Kidney Disease Epidemiology Collaboration creatinine equation. 10 Inputs for the PCEs model included age, sex, race, systolic BP, total cholesterol, high‐density lipoprotein cholesterol, hypertension treatment status, diabetes status, and current smoking status. 11 Detailed model parameters for the PREVENT equations and PCEs are provided in Tables S2 and S3, respectively.
For descriptive analyses, characteristics were summarized among adults with untreated stage 1 hypertension. Individuals were categorized into 4 mutually exclusive groups based on guideline‐defined risk thresholds: PREVENT <7.5% and PCEs <10% (below the pharmacotherapy threshold under both guidelines), PREVENT <7.5% and PCEs ≥10% (formerly eligible for treatment under the 2017 guideline only), PREVENT ≥7.5% and PCEs <10% (newly eligible for treatment under the 2025 guideline only), and PREVENT ≥7.5% and PCEs ≥10% (eligible for pharmacotherapy under both guidelines). Continuous variables were summarized as survey‐weighted means±SEs, and categorical variables as survey‐weighted percentages with 95% CIs, incorporating the NHANES complex sampling design to produce nationally representative estimates.
Among adults with stage 1 hypertension, we quantified the increase in pharmacotherapy eligibility under the 2025 ACC/AHA guideline compared with the 2017 framework. The analysis estimated the proportion and number of adults newly eligible for treatment (PREVENT ≥7.5% and PCEs <10%) in the overall stage 1 hypertension population and among those who were untreated.
Adopting a population‐impact estimation approach similar to that described by Bress et al., 12 we applied externally derived CVD event rates for stage 1 hypertension to quantify the number of CVD events potentially preventable due to the transition from the 2017 PCE‐based guideline to the 2025 PREVENT‐based guideline. Specifically, a 10‐year CVD rate of 2.80% was multiplied by the NHANES‐weighted population size to estimate expected 10‐year events in the absence of intervention, and the lifetime CVD rate (16.61%) was used to contextualize long‐term disease burden. 13
As a sensitivity analysis (Figure S1), all analyses described here were repeated restricting the cohort to adults aged 40 to 79 years, consistent with the validated age range of the PCEs. All analyses incorporated the NHANES complex survey design, including examination weights, strata, and primary sampling units, in accordance with NHANES analytic guidelines using the combined 2015 to 2020 mobile examination center weights.
RESULTS
Study Population and Prevalence of Untreated Stage 1 Hypertension
Among 25 531 NHANES participants from 2015 to 2020, a total of 1926 individuals met eligibility criteria for stage 1 hypertension, corresponding to a weighted national estimate of 32.6 million adults (95% CI, 29.5–35.6; Figure 1). Of these, 59.6% (weighted 19.4 million adults) were untreated. There were 417 762 untreated participants newly eligible for pharmacologic therapy under the 2025 ACC/AHA hypertension guideline, representing 13.8% (95% CI, 7.1–20.6) of adults exceeding the PREVENT 7.5% treatment threshold. This subgroup was predominantly female (69.0% [95% CI, 50.1–87.9]) with a mean age of approximately 60.5 years.
Characteristics of Adults Newly Eligible for Pharmacologic Therapy Under the 2025 Guideline
Compared with adults below the PREVENT 7.5% treatment threshold, those meeting the PREVENT‐based eligibility criteria were older (mean age range, 60.5–65.9 versus 45.5–51.5 years) and had a higher prevalence of diabetes. They also had lower kidney function (mean eGFR range, 84.4–91.1 versus 98.1–99.6 mL/min per 1.73 m2), reflecting a higher cardiometabolic risk profile. A small subset (1.9%, weighted 0.3 million) was eligible under the 2017 PCEs‐based guideline but not under the 2025 PREVENT framework, reflecting differences in underlying model inputs and risk calibration (more detail in Table).
Table 1.
Characteristics of People Aged 30 to 79 Years With Untreated Stage 1 Hypertension According to the 2025 ACC/AHA Guideline in NHANES From 2015 to 2020 (Weighted)*
| Characteristics | Participants, No. (%) (95% CI) | |||
|---|---|---|---|---|
| PREVENT<7.5% | PREVENT≥7.5% | |||
| PCE<10% | PCE≥10% | PCE<10% | PCE≥10% | |
| Untreated (unweighted) | 830 (97.08%) | 25 (2.92%) | 36 (15.25%) | 200 (84.75%) |
| Untreated |
16 078 555 (98.10%) (97.15–99.05) |
311 226 (1.90%) (0.95–2.85) |
417 762 (13.84%) (7.06–20.63) |
2 600 005 (86.16%) (79.37–92.94) |
| Age, y (weighted) | ||||
| Age, mean±SE | 45.53 (0.44) | 51.48 (0.61) | 60.48 (0.77) | 65.87 (0.50) |
| [30–39] |
4 893 260 (30.43%) (26.48–34.38) |
Suppressed | Suppressed |
9486 (0.36%) (0.00–1.12) |
| [40–49] |
5 606 098 (34.87%) (29.47–40.26) |
Suppressed | Suppressed | Suppressed |
| [50–59] |
4 482 026 (27.88%) (23.78–31.97) |
Suppressed | Suppressed |
368 364 (14.17%) (7.83–20.50) |
| [60–69] |
1 097 171 (6.82%) (3.42–10.23) |
Suppressed | Suppressed |
1 080 843 (41.57%) (28.92–54.23) |
| [70–79] |
0 (−) (−) |
Suppressed |
31 167 (7.46%) (3.00–11.92) |
1 043 106 (40.12) (30.91–49.33) |
| Sex (weighted) | ||||
| Female |
7 518 777 (46.76%) (41.43–52.10) |
Suppressed | Suppressed |
731 817 (28.15%) (19.25–37.04) |
| Race (weighted) | ||||
| Non‐Hispanic White |
10 378 223 (64.55%) (59.54–69.56) |
Suppressed | Suppressed |
1 804 341 (69.40%) (60.22–78.57) |
| Non‐Hispanic Black |
1 594 051 (9.91%) (7.46–12.36) |
Suppressed | Suppressed |
225 963 (8.69%) (5.08–12.30) |
| Other† |
4 106 280 (25.54%) (21.47–29.61) |
Suppressed | Suppressed |
569 701 (21.91%) (14.46–29.36) |
| Health conditions (weighted) | ||||
| Diabetes |
659 428 (4.10%) (3.01–5.20) |
Suppressed | Suppressed |
718 327 (27.63%) (17.61–37.64) |
| Current smoker |
2 980 900 (18.54%) (13.69–23.39) |
Suppressed | Suppressed |
762 681 (29.33%) (19.23–39.44) |
| Statin use |
878 688 (5.47%) (2.78–8.15) |
Suppressed | Suppressed |
395 880 (15.23%) (8.17–22.28) |
| Laboratory values (weighted): mean±SD | ||||
| Estimated glomerular filtration rate, mL/min per 1.73 m2 | 99.58 (0.87) | 98.06 (0.17) | 91.11 (1.42) | 84.43 (1.61) |
| Total cholesterol, mg/dL | 202.41 (2.35) | 219.98 (3.87) | 184.03 (5.14) | 208.34 (3.89) |
| High‐density lipoprotein cholesterol, mg/dL | 53.84 (0.83) | 35.11 (1.59) | 54.71 (1.37) | 52.42 (1.01) |
ACC/AHA indicates American College of Cardiology/American Heart Association; NHANES, National Health and Nutrition Examination Survey; PCE, pooled cohort equation; and PREVENT, Predicting Risk of Cardiovascular Disease Events.
Percentage estimates that did not meet National Center for Health Statistics reliability criteria for data presentation, including an unweighted sample size <30 or excessive 95% CI width, were suppressed. Estimates from discordant PREVENT and PCE groups are based on small, unweighted sample sizes and should be interpreted with caution.
Other includes Mexican American, Other Hispanic, Non‐Hispanic Asian, and other races, including multiracial individuals.
Expansion of Treatment Eligibility Under the 2025 Compared With the 2017 Guideline
Under the 2025 PREVENT‐based hypertension guideline, treatment recommendations were largely concordant with the 2017 PCE‐based framework, and additional individuals became eligible for pharmacotherapy (Figure 2). In our analytic cohort, 10.6 million were recommended for pharmacologic therapy under either guideline, including 8.2 million (77.4%) who were already eligible under the 2017 guideline and an additional 2.4 million (22.6%) who became newly eligible based on a PREVENT 10‐year CVD risk ≥7.5%. When restricted to those with untreated stage 1 hypertension, 3.3 million adults met treatment eligibility under either guideline, of whom 2.9 million (87.5%) were previously eligible and 0.4 million (12.5%) were newly identified by the PREVENT model. However, this newly eligible population was partially offset by ∼0.3 million adults who were eligible under the 2017 PCE‐based framework but would no longer be eligible under PREVENT, yielding a net increase of approximately 0.1 million adults recommended for pharmacologic therapy compared with the 2017 PCE‐based framework.
Figure 2. Additional people recommended to receive pharmacotherapy based on the 2025 ACC/AHA guideline among adults with stage 1 hypertension overall, and untreated.

Old eligible is defined as PCE 10‐year ASCVD risk ≥10%. New eligible is defined as PCE 10‐year ASCVD risk <10% and PREVENT 10‐year CVD risk score ≥7.5%. Old eligible includes individuals who were eligible under the 2017 PCE‐based guideline but are not eligible under the 2025 PREVENT guideline. ACC/AHA indicates American College of Cardiology/American Heart Association; ASCVD, atherosclerotic cardiovascular disease; CVD, cardiovascular disease; M, million; PCE, pooled cohort equation; and PREVENT, Predicting Risk of Cardiovascular Disease Events.
Potential CVD Events Preventable Following the Transition From PCEs to PREVENT
The transition from the 2017 PCE to 2025 PREVENT model identified 2 406 309 additional individuals newly eligible for antihypertensive treatment. Applying externally derived CVD risk estimates, treatment of this newly eligible population could potentially prevent approximately 67 377 CVD events over 10 years and 399 688 CVD events over the long term (Figure 3).
Figure 3. Potential CVD events preventable by the transition from PCE (2017) to PREVENT (2025).

CVD rate estimates were externally derived from existing literature (10‐year=2.80%; long‐term [lifetime]=16.61%). CVD indicates cardiovascular disease; PCE, pooled cohort equation; and PREVENT, Predicting Risk of Cardiovascular Disease Events.
Sensitivity Analysis
Findings were consistent in sensitivity analyses restricted to adults aged 40 to 79 years, with similar estimates of newly eligible individuals and comparable numbers of cardiovascular events potentially preventable by transitioning from the PCE‐based to the PREVENT‐based framework (Figures S2 and S3).
DISCUSSION
Our analysis of NHANES 2015 to 2020 identified an estimated 33 million US adults aged 30 to 79 years with stage 1 hypertension, of whom more than 19 million remained untreated. The 2025 ACC/AHA hypertension guideline adopting the PREVENT model identified ∼23% more adults with stage 1 hypertension as recommended for treatment. An estimated 3.3 million untreated adults would qualify for pharmacologic treatment, of whom 0.42 million were newly eligible compared with the older guidelines, though the net increase was smaller after accounting for those who were eligible under the older guideline but would no longer be eligible under PREVENT. These untreated but treatment‐eligible adults were typically older and had greater cardiometabolic burden, including higher prevalence of diabetes and reduced kidney function, which were not fully captured under the prior PCEs‐based framework, suggesting that the PREVENT model identifies cardiovascular risk more comprehensively in this population.
Beyond expanding population recommended for treatments, the transition from the PCEs to the PREVENT model has important implications for population‐level CVD prevention, with the potential to prevent ∼67 377 CVD events over 10 years and 399 688 events over the long term. This highlights the value of PREVENT‐based risk assessment in identifying future‐high‐risk individuals earlier and supporting more proactive, prevention‐oriented hypertension management.
Despite the refinement of hypertension guidelines, an estimated 2.6 million US adults with stage 1 hypertension were recommended for pharmacologic treatment under the 2017 guideline remain untreated nationwide. Consistent with prior evidence, national data show that fewer than one third of adults with stage 1 hypertension eligible for medication receive it. 14 , 15 , 16 Globally, lack of adherence remains a major barrier to hypertension control, with ∼45% of adults with hypertension being nonadherent to prescribed antihypertensive therapy. 17 This persistent treatment gap reflects substantial clinical inertia in the management of early hypertension and underscores that expanding population recommended for treatment under the 2025 guideline alone may be insufficient to meaningfully improve treatment uptake. Without appropriate management, patients with stage 1 hypertension progress to stage 2 hypertension within 2 to 7 years, depending on age, comorbidities, and lifestyle behaviors. 13 , 18 , 19 Stage 2 hypertension (≥140/90 mm Hg) itself is associated with substantially higher risks of organ damage, such as chronic kidney disease, myocardial infarction, and stroke. 20 , 21 Meanwhile, untreated hypertension further elevates all‐cause mortality (hazard ratio [HR], 1.40–1.62) and CVD‐specific mortality (HR, 1.77–2.23), driven by increased risk on both heart disease (HR, 1.69–2.19) and stroke (HR, 2.53–3.01). 13 , 22
Among adults with stage 1 hypertension and a PREVENT risk <7.5%, the mean eGFR remained lower than 100 mL/min per 1.73 m2, reflecting preserved kidney function that is lower than typically observed in healthy populations. 23 Additionally, adults meeting the PREVENT ≥7.5% treatment threshold had mean eGFR values of 84 to 91 mL/min per 1.73 m2, indicating a further reduction in renal function within the normal‐to‐mildly reduced range. 23 Although albuminuria was not available to formally classify chronic kidney disease stage, this gradient in eGFR across risk strata suggests that subclinical renal deterioration may already be present among adults with stage 1 hypertension and that individuals newly recommended for treatment represent a population with heightened renal vulnerability. Additionally, according to our national estimates, stage 1 patients recommended for treatment under 2025 guideline exhibited a considerable metabolic burden. Diabetes was present in ∼876 008 treatment‐recommended but untreated adults in our sample (20%–38%), underscoring the high prevalence of metabolic comorbidity even before antihypertensive treatment initiation. Collectively, this cardiometabolic and renal profile reinforces the need to prioritize metabolically and renally favorable antihypertensive agents at treatment initiation. Per the 2025 AHA/ACC guideline, initial antihypertensive therapy should be selected from thiazide and thiazide‐like diuretics, long‐acting dihydropyridine calcium channel blockers, angiotensin‐converting enzyme inhibitors, or angiotensin receptor blockers, considering comorbidities and compelling indications. 5 Given the high prevalence of diabetes and early renal impairment in this population, initial selection should favor agents with neutral metabolic profiles and proven renal benefits. In this context, angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers are advantageous given the cardiorenal protective effects 24 , 25 and improved insulin sensitivity through inhibition of angiotensin II–mediated oxidative stress, 26 , 27 and have been associated with a neutral or even lower risk of new‐onset diabetes. 28 Long‐acting dihydropyridine calcium channel blockers, which are also metabolically neutral, 28 may serve as suitable alternatives or add‐on options when additional BP control is needed or when renin‐angiotensin system inhibitors are contraindicated. In contrast, thiazide diuretics and β‐blockers should be used with caution, given consistent evidence of higher fasting glucose, reduced insulin secretion, and impaired insulin sensitivity. 29 , 30 , 31
Strengths and Limitations
To our knowledge, this is the first study to quantify the population‐level impact of the 2025 ACC/AHA guideline on adults with stage 1 hypertension who would become newly eligible for pharmacologic treatment. Leveraging a nationally representative population and 2 validated cardiovascular risk algorithms, the PREVENT and the PCEs, we identified the magnitude of reclassification and characterized the clinical profiles of those newly eligible under the updated guideline. We further estimated the number of potential cardiovascular events that could be prevented by transitioning from PCE‐based to PREVENT‐based treatment recommendations.
Among its multiple strengths, this analysis has limitations. First, to compute PREVENT risk we conducted a complete‐case analysis, excluding participants missing any required inputs. This approach minimizes risk‐classification error but reduces the analytic sample and may yield conservative (lower) national estimates. Nevertheless, comparison of participants included in the final analytic cohort with those excluded due to missing variables showed broadly similar demographic and clinical characteristics (Table S4). These patterns suggest that exclusions likely did not introduce substantial clinical differences but may reflect disparities in access to laboratory testing associated with social vulnerability (eg, women, racial minority groups). Additionally, although the NHANES 2015 to March 2020 cycles include data collected after the release of the 2017 ACC/AHA hypertension guideline, uptake of guideline recommendations in clinical practice may require time, given the 2019 to March 2020 cycle was cut short as well as the unique complex, multistage probabilistic sampling and cross‐sectional nature of NHANES, our findings may not exactly reflect the nationwide temporal changes in adoption.
CONCLUSIONS
The 2025 ACC/AHA hypertension guideline employing the PREVENT model yields largely concordant pharmacotherapy recommendations while identifying additional treatment‐recommended adults with untreated stage 1 hypertension. Within this newly treatment‐eligible population, individuals meeting the PREVENT ≥7.5% threshold demonstrate early signs of renal decline and a considerable metabolic burden, revealing that cardiometabolic or renal vulnerability is already present at modest elevations of BP. These findings highlight the potential implications of earlier detection and treatment, underscoring the need to evaluate whether new eligibility criteria translate into improved clinical outcomes.
Sources of funding
None.
Disclosures
None.
Supporting information
Tables S1–S4
Figures S1–S3
Acknowledgment
None.
This article was sent to Tochukwu M. Okwuosa, DO, Associate Editor, for review by expert referees, editorial decision, and final disposition.
Supplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.125.049525
For Disclosures, see page 9.
References
- 1. He C, Lu S, Yu H, Sun Y, Zhang X. Global, regional, and national disease burden attributable to high systolic blood pressure in youth and young adults: 2021 Global Burden of Disease study analysis. BMC Med. 2025;23:74. doi: 10.1186/s12916-025-03918-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. World Health Organization . Hypertension. World Health Organization; 2025. Accessed October 9, 2025. https://www.who.int/news‐room/fact‐sheets/detail/hypertension [Google Scholar]
- 3. Kario K, Okura A, Hoshide S, Mogi M. The WHO global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy. Hypertens Res © 2024. The Author(s), under exclusive licence to The Japanese Society of Hypertension. 2024;5:1099–1102. doi: 10.1038/s41440-024-01622-w [DOI] [PubMed] [Google Scholar]
- 4. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension. 2018;71:e13–e115. doi: 10.1161/hyp.0000000000000065 [DOI] [PubMed] [Google Scholar]
- 5. Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, Altieri MM, Bansal N, Bello NA, Bress AP, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Hypertension. 2025;82:e212–e316. doi: 10.1161/hyp.0000000000000249 [DOI] [PubMed] [Google Scholar]
- 6. Medina‐Inojosa JR, Somers VK, Garcia M, Thomas RJ, Allison T, Chaudry R, Wood‐Wentz CM, Bailey KR, Mulvagh SL, Lopez‐Jimenez F. Performance of the ACC/AHA pooled cohort cardiovascular risk equations in clinical practice. J Am Coll Cardiol. 2023;82:1499–1508. doi: 10.1016/j.jacc.2023.07.018 [DOI] [PubMed] [Google Scholar]
- 7. Khera R, Pandey A, Ayers CR, Carnethon MR, Greenland P, Ndumele CE, Nambi V, Seliger SL, Chaves PHM, Safford MM, et al. Performance of the pooled cohort equations to estimate atherosclerotic cardiovascular disease risk by body mass index. JAMA Netw Open. 2020;3:e2023242. doi: 10.1001/jamanetworkopen.2020.23242 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Centers for Disease Control and Prevention. National Center for Health Statistics . NHANES Tutorials – Sample Design Module. n.d.
- 9. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension. 2018;71:1269–1324. doi: 10.1161/hyp.0000000000000066 [DOI] [PubMed] [Google Scholar]
- 10. Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, Blaha MJ, Carson AP, Chang AR, Ciemins E, et al. Development and validation of the American Heart Association's PREVENT equations. Circulation. 2024;149:430–449. doi: 10.1161/circulationaha.123.067626 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Goff DC Jr, Lloyd‐Jones DM, Bennett G, Coady S, D'agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'donnell CJ, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S49–S73. doi: 10.1161/01.cir.0000437741.48606.98 [DOI] [PubMed] [Google Scholar]
- 12. Bress AP, Colantonio LD, Cooper RS, Kramer H, Booth JN III, Odden MC, Bibbins‐Domingo K, Shimbo D, Whelton PK, Levitan EB, et al. Potential cardiovascular disease events prevented with adoption of the 2017 American College of Cardiology/American Heart Association blood pressure guideline. Circulation. 2019;139:24–36. doi: 10.1161/circulationaha.118.035640 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Peng X, Jin C, Song Q, Wu S, Cai J. Stage 1 hypertension and the 10‐year and lifetime risk of cardiovascular disease: a prospective real‐world study. J Am Heart Assoc. 2023;12:e028762. doi: 10.1161/jaha.122.028762 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Flatow JS, Byfield R, Singer J, Chang MJ, Schwartz JE, Shimbo D, Kronish IM. Clinical inertia in the diagnosis and management of hypertension following ambulatory blood pressure monitoring. Am J Hypertens. 2025;38:280–287. doi: 10.1093/ajh/hpae157 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Ali DH, Kiliç B, Hart HE, Bots ML, Biermans MCJ, Spiering W, Rutten FH, Hollander M. Therapeutic inertia in the management of hypertension in primary care. J Hypertens. 2021;39:1238–1245. doi: 10.1097/hjh.0000000000002783 [DOI] [PubMed] [Google Scholar]
- 16. Lu Y, Arowojolu O, Qiu X, Liu Y, Curry LA, Krumholz HM. Barriers to optimal clinician guideline adherence in management of markedly elevated blood pressure: a qualitative study. JAMA Netw Open. 2024;7:e2426135. doi: 10.1001/jamanetworkopen.2024.26135 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Abegaz TM, Shehab A, Gebreyohannes EA, Bhagavathula AS, Elnour AA. Nonadherence to antihypertensive drugs: a systematic review and meta‐analysis. Medicine (Baltimore). 2017;96:e5641. doi: 10.1097/md.0000000000005641 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Boateng GO, Lartey ST, Baiden P, Si L, Biritwum RB, Kowal P, Magnussen CG, Ben Taleb Z, Palmer AJ, Luginaah I. Measuring hypertension progression with transition probabilities: estimates from the WHO SAGE longitudinal study. Front Public Health. 2021;9:571110. doi: 10.3389/fpubh.2021.571110 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Yu ES, Hong K, Chun BC. A longitudinal analysis of the progression from normal blood pressure to stage 2 hypertension: a 12‐year Korean cohort. BMC Public Health. 2021;21:61. doi: 10.1186/s12889-020-10115-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Lee H, Cho SMJ, Park JH, Park S, Kim HC. 2017 ACC/AHA blood pressure classification and cardiovascular disease in 15 million adults of age 20‐94 years. J Clin Med. 2019;8:1832. doi: 10.3390/jcm8111832 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Wu CY, Hu HY, Chou YJ, Huang N, Chou YC, Li CP. High blood pressure and all‐cause and cardiovascular disease mortalities in community‐dwelling older adults. Medicine (Baltimore). 2015;94:e2160. doi: 10.1097/md.0000000000002160 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Zhou D, Xi B, Zhao M, Wang L, Veeranki SP. Uncontrolled hypertension increases risk of all‐cause and cardiovascular disease mortality in US adults: the NHANES III linked mortality study. Sci Rep. 2018;8:9418. doi: 10.1038/s41598-018-27377-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, Zeeuw DDE, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–2100. doi: 10.1111/j.1523-1755.2005.00365.x [DOI] [PubMed] [Google Scholar]
- 24. Kobori H, Mori H, Masaki T, Nishiyama A. Angiotensin II blockade and renal protection. Curr Pharm Des. 2013;19:3033–3042. doi: 10.2174/1381612811319170009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, Jia J, Yan T, Liu Y, Lin S. ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non‐dialysis chronic kidney disease stages 3‐5: a network meta‐analysis of randomised clinical trials. Drugs. 2020;80:797–811. doi: 10.1007/s40265-020-01290-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin‐converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol. 2003;91(12a):30h–37h. doi: 10.1016/s0002-9149(03)00432-6 [DOI] [PubMed] [Google Scholar]
- 27. Jandeleit‐Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin‐angiotensin system reduces the incidence of new‐onset diabetes. J Hypertens. 2005;23:463–473. doi: 10.1097/01.hjh.0000160198.05416.72 [DOI] [PubMed] [Google Scholar]
- 28. Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta‐analysis of randomized clinical trials. J Am Coll Cardiol. 2005;46:821–826. doi: 10.1016/j.jacc.2005.05.051 [DOI] [PubMed] [Google Scholar]
- 29. Rehman A, Setter SM, Vue MH. Drug‐induced glucose alterations part 2: drug‐induced hyperglycemia. Diabetes Spectr. 2011;24:234–238. doi: 10.2337/diaspect.24.4.234 [DOI] [Google Scholar]
- 30. Karnes JH, Gong Y, Arwood MJ, Gums JG, Hall KL, Limacher MC, Johnson JA, Cooper‐DeHoff RM. Alteration in fasting glucose after prolonged treatment with a thiazide diuretic. Diabetes Res Clin Pract. 2014;104:363–369. doi: 10.1016/j.diabres.2014.04.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Widiarti W, Saputra PBT, Savitri CG, Putranto JNE, Alkaff FF. The impact of cardiovascular drugs on hyperglycemia and diabetes: a review of ‘unspoken’ side effects. Hell J Cardiol. 2025;83:71–77. doi: 10.1016/j.hjc.2024.09.007 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Tables S1–S4
Figures S1–S3
